Calamos Advisors LLC Sells 28,715 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Calamos Advisors LLC lowered its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 24.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 86,501 shares of the medical research company’s stock after selling 28,715 shares during the period. Calamos Advisors LLC’s holdings in IQVIA were worth $20,015,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. AdvisorNet Financial Inc grew its holdings in shares of IQVIA by 327.6% during the 4th quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 95 shares during the last quarter. BKM Wealth Management LLC purchased a new position in shares of IQVIA in the fourth quarter worth $32,000. Activest Wealth Management bought a new stake in IQVIA during the 4th quarter valued at $35,000. Live Oak Investment Partners purchased a new stake in IQVIA during the 4th quarter valued at $41,000. Finally, CVA Family Office LLC bought a new stake in IQVIA in the 4th quarter worth $43,000. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on IQV. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Evercore ISI boosted their price objective on shares of IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a research report on Thursday, February 15th. Guggenheim cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Thursday, February 15th. Truist Financial boosted their price objective on shares of IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Finally, UBS Group boosted their price objective on shares of IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $256.80.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,000 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Eric Sherbet sold 1,000 shares of the firm’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the transaction, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kevin C. Knightly sold 8,607 shares of the firm’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the transaction, the insider now directly owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The disclosure for this sale can be found here. Insiders sold a total of 41,285 shares of company stock valued at $10,331,003 over the last three months. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Up 0.8 %

Shares of NYSE IQV traded up $1.81 during midday trading on Friday, hitting $228.98. The stock had a trading volume of 71,084 shares, compared to its average volume of 957,008. The company has a market cap of $41.56 billion, a P/E ratio of 31.16, a PEG ratio of 2.20 and a beta of 1.50. The business’s 50 day moving average is $244.62 and its 200-day moving average is $221.41. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.02. The business had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The company’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period last year, the firm earned $2.54 earnings per share. As a group, analysts predict that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.